Fund Manager Summary on Healius Ltd (ASX:HLS)
In December 2025, Wentworth Williamson commented that they initiated a modest position in Healius reflecting conviction in a medium-term turnaround and value-realisation potential. Healius Ltd (ASX:HLS) fund manager commentary through 2025 converges on a view that the $965 million sale of the Lumus Imaging division materially resets the balance sheet—creating roughly $450 million of net cash and supporting a >$300 million special dividend with $160 million of franking credits—while leaving a pure-play pathology business with ~A$1.3 billion revenue that faces near-term headwinds and execution risk; managers note current EBIT margins are compressed at ~1% (versus a 7–10% peer benchmark) due to deliberate investments in labour, technology and pathology remuneration and that achieving the company’s target of high single-digit margins by mid-2027 will be key to rebuilding confidence, with Tamim and Perpetual highlighting actionable levers such as rostering, collection-centre productivity (closures reduced 50%), consumables and lab infrastructure, a $20 million tech program targeting 15–20% productivity gains, cost discipline and balance-sheet flexibility to pursue either a turnaround or strategic consolidation (e.g. ACL), while key risks to monitor are structural reductions in industry revenue from Medicare rebate changes (~$100 million industry impact), sustained post‑COVID lower testing volumes, heightened political/regulatory scrutiny limiting price pass-through, and management execution on margin recovery and capital returns.
Commentary From The Managers
There are 7 insights from 4 fund managers regarding their investment in Healius Ltd (ASX:HLS) available on Thesis Tracker.
Unlock Updates With ThesisTracker Pro
Don’t let information asymmetry undermine your investment returns. Join other engaged investors on ThesisTracker Pro.
Updates are made available to members within 12 hours of being released. The completeness, accuracy or current status of the investments referenced are not guaranteed.
Commentary From The Managers
Wentworth Williamson
31 Dec 2025
$0.91
Summary
- Wentworth Williamson believes Healius offers a compelling medium-term turnaround and value-realisation potential, and initiated a position because the current share price understates the company’s recovery and optionality; we also initiated a modest position in Healius (ASX:HLS) during the quarter, reflecting our conviction in their medium-term turnaround and value-realisation potential.
- Business mix: core diagnostic and community healthcare operations provide resilient revenue streams and clear levers for margin recovery.
- Management catalysts: visible focus on portfolio simplification, cost discipline and operational improvements should drive earnings and unlock non-core asset value.
- Valuation opportunity: the stock appears to trade at a discount to intrinsic value; recovery in volumes, margins or crystallisation of assets could deliver material upside.
- Cash flow & balance sheet: improving cash generation is expected to enable deleveraging, reinvestment in the business or potential shareholder returns over time.
- Position sizing: the initial holding is modest to participate in the potential upside while managing execution risk.
- Key risks: execution risk, regulatory/reimbursement changes and slower-than-expected demand normalisation could delay value realisation; monitoring of management delivery and near-term catalysts is essential.
Perpetual Asset Management
31 July 2025
$0.77
Summary
- Healius experienced a share decline of –10.1%, impacted by market focus on structural challenges.
- Key issues include lower post-COVID testing volumes and sustained cost pressures in pathology.
- Uncertainty regarding margin stabilisation and earnings recovery has also affected sentiment.
- Despite challenges, Healius remains strategically important due to its national network and exposure to long-term diagnostic demand.
- Streamlining initiatives and balance-sheet actions could support a potential recovery.
- In contrast, Persimmon showed resilience amid subdued sentiment in the UK housing market.
- The company has diversified revenue streams, reducing reliance on government schemes.
- Improving underlying demand is noted as mortgage rates trend lower, indicating potential for an autumn pickup.
- As a top-three UK housebuilder, Persimmon has defended margins through cycles with a sizeable land bank.
- Bulk-sale partnerships provide visibility and flexibility, enhancing the risk-reward profile at current valuations.
Perpetual Asset Management
30 June 2025
$0.79
Summary
- Healius Limited detracted from portfolio performance over the quarter, down 23.1%.
- Investor sentiment is impacted by regulatory uncertainty, earnings pressure, and political scrutiny.
- The sale of Lumus Imaging for $965 million improved balance sheet, enabling a $300 million return to shareholders via a fully franked special dividend.
- Post-dividend, the stock experienced a sharp decline due to concerns over its pathology business.
- Sector-wide changes to Medicare rebates are expected to reduce annual revenue by approximately $100 million.
- Healius is particularly exposed to these changes due to its domestic focus.
- Increased risk of regulatory action from the federal government regarding cost pass-throughs to patients.
- Despite challenges, Healius’s stronger financial position post-divestment offers optionality.
- Perpetual Asset Management continues to hold because they are closely monitoring the evolving operating environment and cost dynamics.
Tamim Funds Management
3 Apr 2025
$1.41
Summary
- Tamim Funds Management highlights that Healius Ltd is undergoing a significant transformation, positioning it for substantial shareholder value creation.
- The impending completion of the $965 million Imaging division sale will leave the company with over $450 million in net cash.
- This financial position paves the way for a capital return of $300 million+, enhanced by $160 million in franking credits.
- The sale allows Healius to present a cleaner narrative as a pure-play pathology business generating approximately $1.3 billion in annual revenue.
- Current EBIT margins are around 1%, significantly below the industry standard of 7-10%, primarily due to self-inflicted margin compression from investments in labor and technology.
- As investments in upgrades near completion and workforce optimization progresses, earnings power is expected to rebound.
- The company's strong balance sheet and capital return are anticipated to act as short-term catalysts for growth.
- Tamim believes a strategic acquisition is likely, with a potential merger with Australian Clinical Labs (ASX: ACL) offering scale synergies.
- The sum-of-parts valuation suggests at least 40% upside, making Healius a prime candidate for either a turnaround-led re-rating or a strategic sale.
Perpetual Asset Management
31 Mar 2025
$1.40
Summary
- Healius contributed positively to portfolio performance, rallying 8.6% in the month.
- During March's investor day, Healius presented a clear capital management plan following the Lumus sale.
- Proceeds from the Lumus sale will be used to pay down debt, with surplus capital returned to shareholders.
- The target to achieve high single-digit EBIT margins by June 2027 is ambitious, considering past execution challenges.
- Operational improvements in rostering, consumables, and lab infrastructure indicate a solid foundation for growth.
- Plans to reduce digital investment and eliminate stranded costs post-sale reflect a commitment to increased cost discipline.
- Execution over the next 12 months will be crucial for building market confidence.
Tamim Funds Management
28 Feb 2025
$1.29
Summary
- Healius (ASX: HLS) is Australia’s 2nd largest pathology provider undergoing a critical transformation phase.
- Current challenges are masking substantial long-term value creation opportunities.
- 1H FY25 results show a strategic pivot aimed at improving operational efficiency and margin performance.
- The pathology division is facing compressed EBIT margins around 1%, significantly below the market benchmark of 7-10%.
- Revenue base is close to $1.3 Billion, with a 7% revenue growth driven by a 5% volume increase and 45% surge in genomic diagnostics.
- Strategic investments focus on workforce optimisation, collection center productivity, and specialist revenue stream development.
- Margin compression results from deliberate investments in labor cost restructuring and call center technology.
- Despite short-term pressures, significant upside potential exists with operational efficiency gains.
- Collection center closures have been reduced by 50%, with a $20 million investment in technology targeting 15-20% productivity gains.
- The pending Imaging division sale for $965 million offers strategic flexibility, with net proceeds exceeding $800 million.
- A potential special dividend over $300 million is anticipated, with $160 million of franking credits available for distribution.
- The March investor day will be crucial for insights into the transformation roadmap.
- Post-imaging sale, the company is expected to have $450 million of net cash, with a current market cap of $950 million.
- A $350 million+ fully franked dividend is anticipated, implying an EV for the remaining pathology business of $350-$450 million.
- Under the right management, a pathology business generating such revenue should yield EBIT margins of 8-10%, suggesting $100 million of potential earnings upside.
- There is uncertainty regarding the current management's capability to execute this strategy.
- A renewed merger offer with Australian Clinical Labs (ACL) presents strategic sense with material synergies.
- Tamim Funds Management believes there’s 40% upside to the current valuation in the near term.
Spheria Asset Management
30 June 2024
$1.44
Summary
- Spheria Asset Management notes that Healius (HLS.ASX) share price increased by 18% during the month.
- The company provided a trading update for 2024 financial year, indicating significant second half improvement in operating performance.
- Healius expects to generate $60-65m of underlying EBIT for the full year to 30 June 2024.
- Improving pathology volumes, moderate inflation rates, and focus on costs and productivity contribute to margin improvement.
- The imaging business is currently for sale, attracting interest from multiple parties, enhancing competitive tension.
- Sale proceeds are expected to leave Healius with a net cash balance sheet.
- As the second largest player in Australia’s pathology market, with the top three comprising ~70%, Spheria remains optimistic.
- Spheria Asset Management is attracted to Healius over the long term and sees potential for material upside to the current share price.
The completeness, accuracy or current status of the investments referenced are not guaranteed.
Frequently Asked Questions
Who is investing in Healius Ltd (ASX:HLS)?
Fund managers including Spheria Asset Management, Perpetual Asset Management, Tamim Funds Management and Wentworth Williamson have invested in Healius Ltd (ASX:HLS).
Why do fund managers invest in Healius Ltd?
Fund managers invest in Healius Ltd due to its position as Australia's second-largest pathology provider, with a significant transformation underway aimed at improving operational efficiency and margins. The recent sale of its Imaging division enhances its balance sheet, providing over $450 million in net cash for potential shareholder returns. Despite current margin pressures of around 1%, there are clear pathways to achieve higher EBIT margins in the future. The company also benefits from long-term diagnostic demand in a crucial healthcare sector, presenting a notable risk/reward profile.
What happened to Healius Ltd (ASX:HLS)?
There have been no recent updates from fund managers regarding Healius Ltd although fund managers including Spheria Asset Management, Perpetual Asset Management and Tamim Funds Management have previously commented.
What is the short interest in Healius Ltd (ASX:HLS)?
The short interest in Healius Ltd (ASX:HLS) is 3.94% which makes it the 59th most shorted stock on the ASX. Of the 726.1M shares that Healius Ltd has on issue, 28.6M have been sold short.
What does Healius Ltd (ASX:HLS) do?
Healius Ltd. engages in the provision of healthcare technology solutions. It operates through the following segments: Pathology, Imaging, and Other. The Pathology segment provides pathology services. The Imaging segment focuses on imaging services from stand-alone imaging sites, hospitals, and medical centers. The Other segment consists of corporate functions. The company was founded by Edmund Gregory Thomas Bateman in 1985 and is headquartered in Sydney, Australia.